Pegasys Related Clinical Trials
A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. [Active, not recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). [Completed]
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C. [Active, not recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection. [Active, not recruiting]
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy [Completed]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin [Completed]
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. [Completed]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. [Completed]
Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV [Active, not recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. [Completed]
A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. [Active, not recruiting]
Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-Infected Patients [Active, not recruiting]
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. [Active, not recruiting]
PEAK Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). [Completed]
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. [Completed]
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C [Completed]
Efficacy and Safety of Telbivudine in Treatment naïve Patients With HBeAg-Positive Chronic Hepatitis B (CHB) [Terminated]
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection [Recruiting]
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C [Active, not recruiting]
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection [Recruiting]
Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection [Recruiting]
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients [Completed]
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. [Recruiting]
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment [Active, not recruiting]
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C [Completed]
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 HCV [Recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. [Recruiting]
Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin [Recruiting]
Pegasys and Copegus for Asian Patiens With Treatment-Naive Hepatitis C Genotypes 6, 7, 8, 9 [Active, not recruiting]
IMPROVE Study(The Individualized Management With PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3. [Recruiting]
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. [Recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB). [Recruiting]
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B [Recruiting]
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer [Completed]
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by Rapid Virologic Response (RVR) [Recruiting]
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer [Active, not recruiting]
Peg-Ifn Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471AM1)(COMPLETED) [Completed]
SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB). [Recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. [Recruiting]
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). [Recruiting]
Pegasys® in Patients With Myeloproliferative Diseases [Recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. [Recruiting]
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients [Not yet recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. [Recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure. [Recruiting]
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB). [Recruiting]
Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C [Recruiting]
Continuing Treatment With Pegasys and Copegus [Recruiting]
Induction Dosing With Pegylated Interferon Alfa 2a and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 [Active, not recruiting]
Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B [Not yet recruiting]
A Study Evaluating 24-Week Telaprevir-Based Treatment, or Extended Treatment to 48 Weeks, in Chronic Hepatitis C Patients Who Achieve a Rapid Viral Response [Recruiting]
Trial of Pegasys® in Patients With Chronic Hepatitis C [Recruiting]
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-Infected Patients [Recruiting]
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C [Recruiting]
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-Viral Treatment [Recruiting]
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B [Active, not recruiting]
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C [Active, not recruiting]
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C [Active, not recruiting]
Efficacy and Safety of Pegylated Interferon Plus Ribavirin Combination Therapy in Treating Older Patients With Chronic Hepatitis C [Recruiting]
S-Citalopram for the Prevention of PEGASYS-Induced Depression
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients [Active, not recruiting]
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) [Active, not recruiting]
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C [Completed]
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma [Recruiting]
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients [Completed]
Efficacy and Tolerance of Peg-Interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV co-Infected Patients [Recruiting]
Comparison of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 [Recruiting]
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 [Active, not recruiting]
Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C [Completed]
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens [Recruiting]
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients [Recruiting]
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC) [Recruiting]
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy [Active, not recruiting]
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-Coinfected Patients [Recruiting]
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients [Completed]
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B [Completed]
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection [Recruiting]
Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients [Recruiting]
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-Responders to Standard Treatment [Recruiting]
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-naïve Dialysis Patients With Chronic Hepatitis C [Recruiting]
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin [Recruiting]
Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus [Recruiting]
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C [Recruiting]
Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication [Completed]
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection [Recruiting]
Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C [Recruiting]
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma HCV RNA Levels Did Not Respond to Therapy [Recruiting]
The Effects of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833AM2) [Active, not recruiting]
Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a [Active, not recruiting]
Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People [No longer recruiting]
A Study to Compare the Effectiveness and Safety of Telbivudine Used in Combination With Peginterferon Against Peginterferon Used Alone and Against Telbivudine Used Alone. [Not yet recruiting]
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin [No longer recruiting]
Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients Receiving Peg-Interferon Plus Ribavirin [Recruiting]
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) [Active, not recruiting]
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera [Active, not recruiting]
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults [No longer recruiting]
Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C [Completed]
High-Dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 [Recruiting]
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for HCV Genotype 2 or 3 [Recruiting]
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) [Completed]
|
